[1]张 毅),刘艳粉).嵌合抗原受体T细胞治疗实体瘤的现状和挑战[J].郑州大学学报(医学版),2018,(06):701-706.[doi:10.13705/j.issn.1671-6825.2018.09.167]
点击复制

嵌合抗原受体T细胞治疗实体瘤的现状和挑战()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2018年06期
页码:
701-706
栏目:
特约述评
出版日期:
2018-11-20

文章信息/Info

作者:
张 毅12)刘艳粉1)
1)郑州大学第一附属医院生物细胞治疗中心和肿瘤中心 郑州 450052;2)郑州大学生命科学学院 郑州 450001
关键词:
嵌合抗原受体T细胞 实体瘤
DOI:
10.13705/j.issn.1671-6825.2018.09.167

参考文献/References:

[1] GROSS G,WAKS T,ESHHAR Z.Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J].Proc Natl Acad Sci U S A,1989,86(24):10024
[2] GARDNER RA,FINNEY O,ANNESLEY C,et al.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults[J].Blood,2017,129(25):3322
[3] FENG K,GUO Y,DAI H,et al.Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer[J].Sci China Life Sci,2016,59(5):468
[4] LI N,LIU SH,SUN MJ,et al.Chimeric antigen receptor-modified T cells redirected to EphA2 for the immunotherapy of non-small cell lung cancer[J].Transl Oncol,2018,11(1):11
[5] WEI XR,LAI YX,LI J,et al.PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells[J].Oncoimmunology,2017,6(3):e1284722
[6] LOUIS CU,SAVOLDO B,DOTTI G,et al.Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J].Blood,2011,118(23):6050
[7] O'ROURKE DM,NASRALLAH MP,DESAI A,et al.A single dose of peripherally infused EGFRvⅢ-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma[J].Sci Transl Med,2017,9(399):984
[8] AHMED N,BRAWLEY V,HEGDE M,et al.HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma:a phase 1 dose-escalation trial[J].JAMA Oncol,2017,3(8):1094
[9] BROWN CE,ALIZADEH D,STARR R,et al.Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J].N Engl J Med,2016,375(26):2561
[10]BEATTY GL,HAAS AR,MAUS MV,et al.Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies[J].Cancer Immunol Res,2015,3(2):217
[11]FENG KC,GUO YL,LIU Y,et al.Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma[J].J Hematol Oncol,2017,10(1):4
[12]BEATTY GL,O'HARA MH,LACEY SF,et al.Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial[J].Gastroenterology,2018,155(1):29
[13]ZHANG C,WANG Z,YANG Z,et al.Phase Ⅰ escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers[J].Mol Ther,2017,25(5):1248
[14]AHMED N,BRAWLEY VS,HEGDE M,et al.Human epidermal growth factor receptor 2(HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma[J].J Clin Oncol,2015,33(15):1688
[15]SERVAIS EL,COLOVOS C,RODRIGUEZ L,et al.Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients[J].Clin Cancer Res,2012,18(9):2478
[16]KACHALA SS,BOGRAD AJ,VILLENA-VARGAS J,et al.Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma[J].Clin Cancer Res,2014,20(4):1020
[17]TOZBIKIAN G,BROGI E,KADOTA K,et al.Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival[J].PLoS One,2014,9(12):e114900
[18]MORELLO A,SADELAIN M,ADUSUMILLI PS.Mesothelin-targeted CARs: driving T cells to solid tumors[J].Cancer Discov,2016,6(2):133
[19]YARDEN Y,SLIWKOWSKI MX.Untangling the ErbB signalling network[J].Nat Rev Mol Cell Biol,2001,2(2):127
[20]SUN M,SHI H,LIU C,et al.Construction and evaluation of a novel humanized HER2-specific chimeric receptor[J].Breast Cancer Res,2014,16(3):R61
[21]CHI F,WU R,JIN X,et al.HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway[J].Onco Targets Ther,2016,9:2709
[22]JIMENEZ-FONSECA P,CARMONA-BAYONAS A,SANCHEZ LORENZO ML,et al.Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer[J].Gastric Cancer,2017,20(3):465
[23]WICHMANN H,GUTTLER A,BACHE M,et al.Targeting of EGFR and HER2 with therapeutic antibodies and siRNA:a comparative study in glioblastoma cells[J].Strahlenther Onkol,2015,191(2):180
[24]GORE J,IMASUEN-WILLIAMS IE,CONTEH AM,et al.Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model[J].Cancer Lett,2016,379(1):143
[25]MATA M,VERA JF,GERKEN C,et al.Toward immunotherapy with redirected T cells in a large animal model:ex vivo activation, expansion, and genetic modification of canine T cells[J].J Immunother,2014,37(8):407
[26]CHENG M,SANTICH BH,XU H,et al.Successful engineering of a highly potent single-chain variable-fragment(scFv)bispecific antibody to target disialoganglioside(GD2)positive tumors[J].Oncoimmunology,2016,5(6):e1168557
[27]HERBST RS.Review of epidermal growth factor receptor biology[J].Int J Radiat Oncol Biol Phys,2004,59(2 Suppl):21
[28]CHOI BD,SURYADEVARA CM,GEDEON PC,et al.Intracerebral delivery of a third generation EGFRvⅢ-specific chimeric antigen receptor is efficacious against human glioma[J].J Clin Neurosci,2014,21(1):189
[29]MIAO H,CHOI BD,SURYADEVARA CM,et al.EGFRvⅢ-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma[J].PLoS One,2014,9(4):e94281
[30]WANG LA,MA N,OKAMOTO S,et al.Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome[J].Oncoimmunology,2016,5(9):e1211218
[31]DENG Z,WU Y,MA W,et al.Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM[J].BMC Immunol,2015,16:1
[32]MORGAN RA,YANG JC,KITANO M,et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J].Mol Ther,2010,18(4):843
[33]LAMERS CH,SLEIJFER S,VULTO AG,et al.Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase Ⅸ: first clinical experience[J].J Clin Oncol,2006,24(13):e20
[34]BERGER C,FLOWERS ME,WARREN EH,et al.Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation[J].Blood,2006,107(6):2294
[35]DI STASI A,TEY SK,DOTTI G,et al.Inducible apoptosis as a safety switch for adoptive cell therapy[J].N Engl J Med,2011,365(18):1673
[36]VOGLER I,NEWRZELA S,HARTMANN S,et al.An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy[J].Mol Ther,2010,18(7):1330
[37]WANG XL,CHANG WC,WONG CW,et al.A transgene-encoded cell surface polypeptide for selection,in vivo tracking, and ablation of engineered cells[J].Blood,2011,118(5):1255
[38]ROYBAL KT,RUPP LJ,MORSUT L,et al.Precision tumor recognition by T cells with combinatorial antigen-sensing circuits[J].Cell,2016,164(4):770
[39]CHEN C,LI K,JIANG H,et al.Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma[J].Cancer Immunol Immunother,2017,66(4):475
[40]CHEVOLET I,SPEECKAERT R,SCHREUER M,et al.Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma[J].Oncoimmunology,2015,4(3):e982382
[41]KARPER JC,EWING MM,ARENS R,et al.T cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development[J].Circulation,2011,124(21):1965
[42]KHALIL DN,SMITH EL,BRENTJENS RJ.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy[J].Nat Rev Clin Oncol,2016,13(5):273
[43]LIU X,RANGANATHAN R,JIANG S,et al.A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors[J].Cancer Res,2016,76(6):1578
[44]HEGDE UP,MUKHERJI B.Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies[J].Cancer Immunol Immunother,2017,66(9):1113
[45]PARDOLL DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252
[46]ROYCHOUDHURI R,EIL RL,RESTIFO NP.The interplay of effector and regulatory T cells in cancer[J].Curr Opin Immunol,2015,33:101
[47]RUELLA M,KLICHINSKY M,KENDERIAN SS,et al.Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells[J].Cancer Discov,2017,7(10):1154
[48]MICHAUD M,MARTINS I,SUKKURWALA AQ,et al.Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice[J].Science,2011,334(662):1573
[49]SISTIGU A,YAMAZAKI T,VACCHELLI E,et al.Cancer cell-autonomous contribution of type Ⅰ interferon signaling to the efficacy of chemotherapy[J].Nat Med,2014,20(11):1301
[50]ALIZADEH D,TRAD M,HANKE NT,et al.Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer[J].Cancer Res,2014,74(1):104
[51]HIGGINS JP,BERNSTEIN MB,HODGE JW.Enhancing immune responses to tumor-associated antigens[J].Cancer Biol Ther,2009,8(15):1440
[52]BURNETTE BC,LIANG H,LEE Y,et al.The efficacy of radiotherapy relies upon induction of type Ⅰ interferon-dependent innate and adaptive immunity[J].Cancer Res,2011,71(7):2488
[53]COGDILL AP,ANDREWS MC,WARGO JA.Hallmarks of response to immune checkpoint blockade[J].Br J Cancer,2017,117(1):1
[54]ROSEWELL SHAW A,PORTER CE,WATANABE N,et al.Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer[J].Mol Ther,2017,25(11):2440
[55]LI S,SIRIWON N,ZHANG X,et al.Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors[J].Clin Cancer Res,2017,23(22):6982
[56]SERGANOVA I,MOROZ E,COHEN I,et al.Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1/PD-L1 blockade[J].Mol Ther Oncolytics,2016,4:41

备注/Memo

备注/Memo:
【基金项目】河南省医学科技攻关计划普通项目(201702030)
【作者简介】张毅,通信作者,男,1964年4月生,博士,教授,主任医师,研究方向:肿瘤免疫治疗的基础与临床,E-mail:yizhang@zzu.edu.cn
更新日期/Last Update: 2018-11-20